Moreover, in vivo ARID1A-deficient ovarian cancer models exhibit an increased number of tumor-infiltrating lymphocytes, a higher tumor mutation load, and elevated PD-L1 levels [106]. The gene discussed is ARID1A; the disease is neoplasm.